Abstract:
Die vorliegende Erfindung betrifft neue substituierte Oxindol-Derivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung zur Behandlung von Vasopressin-abhängigen Erkrankungen.
Abstract:
The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I' and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT 6 receptor. wherein R 1 is hydrogen or methyl R 2 is hydrogen or methyl R 3 hydrogen, fluorine C 1 -C 2 alkoxy or fluorinated C 1 -C 2 alkoxy; R 4 is hydrogen, C 1 -C 4 alkyl or fluorinated C 1 -C 4 alkyl; R 5 is hydrogen, fluorine, C 1 -C 2 alkyl, fluorinated C 1 -C 2 alkyl, C 1 -C 2 alkoxy or fluorinated C 1 -C 2 alkoxy; and R 6 is hydrogen, fluorine or chlorine.
Abstract:
The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for treating and/or preventing diseases, and to medicaments containing them.
Abstract:
The invention relates to novel oxindole derivatives of general formula (I), wherein substituents A, B, X and Y are defined as in Claim I, medicaments containing said derivatives, and the use thereof in the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.
Abstract:
Carboxylic acid derivatives have the formula (I), in which R to R , X, Y, and Z have the meanings given in the description. Also disclosed is their preparation. These new compounds are useful for controlling diseases.
Abstract:
The invention relates to novel 5,6-disubstituted oxindole derivatives, to pharmaceutical agents containing said components and to the use thereof for producing a medicament.
Abstract translation:本发明涉及新的5,6-二取代的羟吲哚衍生物,含有它们和它们用于制备药物的制造中使用的药物组合物。 其中R1和R2独立地为氢,C1-C3烷基,C1-C3氟烷基,C1-C3烷氧基,C1-C3氟烷氧基,卤素或CN; R3是氢或C1-C4烷基; R4是乙氧基,氟化乙氧基或异丙基; R5是氢或甲基; R6是Br,Cl,F或CN; R 7是Cl,F或CN; R8和R9独立地是C1-C3烷基或C1-C3氟烷基; X 1是O,NH或CH 2; X2和X3是N或CH,条件是X 2和X 3不同时为N; X 4是N或CH; a和b独立地为0,1或2; 且m,n,p为0并且独立地为1,2或3;
Abstract:
Die vorliegende Erfindung betrifft neue 5-Halogen-substituierte Oxindol-Derivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung zur Behandlung von Vasopressin-abhängigen Erkrankungen.
Abstract:
Die vorliegende Erfindung betrifft neue Amidomethyl-substituierte Oxindol-Derivate der Formel (I), diese enthaltende pharmazeutische Mittel und ihre Verwendung zur Behandlung von Vasopressin-abhängigen Erkrankungen, worin R 1 für Wasserstoff, Methoxy oder Ethoxy steht; R 2 für Wasserstoff oder Methoxy steht; R 3 für Wasserstoff, Methyl, Ethyl, n-Propyl oder Isopropyl steht; X 1 und X 2 für N oder CH stehen, unter der Maßgabe, dass X 1 und X 2 nicht gleichzeitig für N stehen.
Abstract translation:本发明涉及式(I)的新颖的酰氨基甲基取代的羟吲哚衍生物,含有它们和它们用于治疗加压素依赖性疾病的方法,其中R1是氢,甲氧基或乙氧基的药物组合物; R 2是氢或甲氧基; R3是氢,甲基,乙基,正丙基或异丙基; X1和X2是N或CH,条件是X1和X2不同时为N.条件
Abstract:
The present invention relates to novel oxindole derivatives of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent.
Abstract:
The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.